Company Overview and News

306
Opiant Pharmaceuticals Appoints Biotech and Pharmaceutical Industry Veteran Richard Daly to Board of Directors

2018-06-12 globenewswire
SANTA MONICA, Calif., June 12, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced the appointment of Richard J. Daly as a non-executive director and a member of the Audit Committee. Mr. Daly has supported the successful launch of 10 drugs during a 27-year career in the biotech and pharmaceutical industry.
SGYP CPRX OPNT SGYPW

3
Opiant Pharmaceuticals to Participate in Opioid Panel at the BIO International Convention

2018-06-04 globenewswire
SANTA MONICA, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced that Roger Crystal, M.D., Opiant’s Chief Executive Officer, will participate in a panel at the BIO International Convention, being held June 4-7, 2018, in Boston, Massachusetts. Dr. Crystal will be a panelist on “Biology of Pain and Addiction – Next Generation Treatments for Pain and Addiction,” which will be held within a broader session, entitled “Opioids: Changing the Paradigm on Treating Pain and Addiction.
OPNT

6
OPNT / Opiant Pharmaceuticals, Inc. 10-Q (Quarterly Report)

2018-05-08 sec.gov
Document UNITED STATES
OPNT

4
Opiant Pharmaceuticals, Inc. Reports First Quarter 2018 Financial Results and Provides Corporate Update

2018-05-08 globenewswire
SANTA MONICA, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today reported financial results for the first quarter ended March 31, 2018, and provided a corporate update.
OPNT

15
OPNT / Opiant Pharmaceuticals, Inc. DEFA14A

2018-04-17 sec.gov
Document UNITED STATES SECURITIES AND EXCHAN
OPNT

12
OPNT / Opiant Pharmaceuticals, Inc. DEF 14A

2018-04-17 sec.gov
Document UNITED STATES SECURITIES AND EXCHAN
OPNT

18
OPNT / Opiant Pharmaceuticals, Inc. S-8

2018-04-11 sec.gov
Document As filed with the Securities and Exchange Commission on April 11, 2018 Registration No. 333-______<
OPNT

23
Will Opiant Pharma Solve The Biggest Crisis That The FDA Is Currently Facing?

2018-04-11 seekingalpha
Opioid epidemic continues to be one of the biggest challenges that the FDA is currently facing.
AMPH MYL OPNT INSY PFE

20
Titan Pharmaceuticals' (TTNP) CEO Sunil Bhonsle on Q4 2017 Results - Earnings Call Transcript

2018-04-03 seekingalpha
Thank you for holding, and welcome to the Titan Pharmaceuticals Fourth Quarter and Full Year 2017 Financial Results Conference Call. [Operator Instructions]. Please be advised that this call is being taped at the company's request and will be archived on the company's website starting later today. At this time, I would like to turn the call over to Sunil Bhonsle, President and CEO of Titan Pharmaceuticals.
OPNT TTNP GUD KHTRF

3
Trump Gives Surprise Plug to Opioid Overdose Antidote Company - Bloomberg

2018-03-20 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
OPNT

Related Articles

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

STML: Stemline Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Stemline Therapeutics was incorporated under the laws of the State of Delaware in August 2003. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers. The company's clinical pipeline includes: SL-401, SL-801, and SL-701. SL-401 pivotal data; plans for registration and potential commercialization: SL-401 has completed a pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and has successfully met the primary endpoint of the trial. SL-401 is a targeted therapy directed to the interleukin-3 receptor-a, or CD123. SL-401 was granted breakthrough therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA, for the treatment of patients with BPDCN. Based on the trial results and other data, the company expect to complete submission of a rolling Biologics License...

CUSIP: 683750103